Poly Medicure Limited (531768) Earnings Call Transcripts

Poly Medicure Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Poly Medicure Limited reported consolidated revenue of INR 534 crores, reflecting a strong 21% year-on-year growth, driven by a robust domestic performance and strategic acquisitions. The company achieved a full-year consolidated revenue of INR 1,875 crores, up 12.3% from the previous year. Management has provided an optimistic revenue guidance for FY '27, projecting consolidated revenues between INR 2,300 crores to INR 2,400 crores, indicating continued growth momentum despite external challenges.

Reported metrics

Guidance from management

For FY '27, Poly Medicure is guiding consolidated revenue of INR 2,300 to INR 2,400 crores and standalone revenue of INR 1,900 to INR 1,950 crores, with EBITDA margins expected to remain between 25% and 27%. This reflects confidence in growth despite external challenges.

What management said

I think headwinds I would say that we have bounced back in Europe. That's what I can tell you right now. we have added quite a few customers in Europe. And also the existing customers where we had an over inventory situation and we had a little slowdown in demand. I think that has come back and currently, last 3, 4 months, we are seeing a good uptake. And I think the pipeline is also very, very strong in Europe. So I...

We don't think in every industry. I think that is the problem across the industry, not in any. But because Polymed we have a lot of products which are very specific things, there are certain patents protection. So I think we are not impacted. See, the demand is not getting demand, which was impacted due to supply chain, last time, I mentioned very specifically that there was, let's say, maybe an oversupply because of...

What analysts pressed on

Analysts expressed concerns regarding the impact of logistical disruptions on export growth and the potential for margin erosion due to rising raw material costs. There were questions about how management plans to navigate competitive pressures, particularly from Chinese imports in the renal segment.

Main topics on the call

• Revenue Growth and Guidance — Poly Medicure reported a consolidated revenue of INR 1,875 crores for FY '26, up 12.3% YoY, with Q4 revenue at INR 534 crores, a 21% increase. Management stated, "we are guiding a revenue of INR 2,000 crores to INR 2,400...
• Gross Margin Trends — The gross margin for Q4 was reported at 66.7%, slightly down from previous quarters due to a product mix issue. Management noted, "the impact of that is primarily to the product mix rather than anything else," indicating...
• Acquisition Strategy — The acquisition of Marine in Brazil for INR 13-15 billion is seen as a strategic entry into the Latin American market, allowing Poly Medicure to bypass lengthy regulatory processes. Management emphasized this acquisition...
• Cost Management Initiatives — Management highlighted ongoing cost-saving projects and optimization strategies to mitigate raw material price increases, stating, "we are already working a lot of cost-saving projects looking at alternate supply sources...

Read the full Poly Medicure Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 Poly Medicure Limited earnings call transcripts on record, spanning February 2, 2024 to August 10, 2026. Based on this history, Poly Medicure Limited reports quarterly. The most recent call on file is dated August 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

531768

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

10

First call

February 2, 2024

Most recent

August 10, 2026

Reporting cadence

quarterly